A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Christopher Murray Biography and Net Worth

Insider of Blueprint Medicines

Chris brings more than 20 years of experience in leading biopharmaceutical product development, manufacturing and supply chain organizations. He joined Blueprint Medicines in 2017 as Senior Vice President, Technical Operations responsible for overseeing all aspects of Chemistry, Manufacturing and Controls (CMC) for the company’s global commercial products and other compounds, as well as CMC management from early preclinical development to commercial launch and distribution. Before joining Blueprint Medicines, Chris held roles of increasing responsibility at ARIAD Pharmaceuticals, leading CMC development for multiple drugs for treatment of cancer from early preclinical stages to global commercial launch and distribution, including overseeing product development, Quality Control, process development, manufacturing, supply chain and logistics, and clinical supply. Prior to that, he managed active pharmaceutical ingredient (API) development, regulatory filings and manufacturing at Allos Therapeutics. Earlier in his career, Chris held multiple positions at Hauser, Inc. overseeing all business, technical and regulatory compliance aspects of contract R&D and manufacturing of clinical and commercial APIs and registered pharmaceutical intermediates. Chris is an inventor or co-inventor on more than 25 U.S. patents. Chris earned a B.S. in Chemistry from Hope College and a Ph.D. in Organic Chemistry from the University of Chicago.

What is Christopher K. Murray's net worth?: The estimated net worth of Christopher K. Murray is at least $3.45 million as of March 4th, 2024. Dr. Murray owns 36,374 shares of Blueprint Medicines stock worth more than $3,448,619 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Murray may own. Additionally, Dr. Murray receives an annual salary of $338,370.00 as Insider at Blueprint Medicines. Learn More about Christopher K. Murray's net worth.
How old is Christopher K. Murray?: Dr. Murray is currently 60 years old. There are 8 older executives and no younger executives at Blueprint Medicines. Learn More on Christopher K. Murray's age.
What is Christopher K. Murray's salary?: As the Insider of Blueprint Medicines Co., Dr. Murray earns $338,370.00 per year. There are 5 executives that earn more than Dr. Murray. The highest earning executive at Blueprint Medicines is Ms. Kathryn Haviland, President, CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on Christopher K. Murray's salary.
How do I contact Christopher K. Murray?: The corporate mailing address for Dr. Murray and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Christopher K. Murray's contact information.
Has Christopher K. Murray been buying or selling shares of Blueprint Medicines?: Christopher K. Murray has not been actively trading shares of Blueprint Medicines in the last ninety days. Most recently, Christopher K. Murray sold 621 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $93.65, for a transaction totalling $58,156.65. Following the completion of the sale, the insider now directly owns 36,374 shares of the company's stock, valued at $3,406,425.10. Learn More on Christopher K. Murray's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (President, CEO & Director), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Philina Lee (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 28 times. They sold a total of 331,047 shares worth more than $31,397,044.73. The most recent insider tranaction occured on October, 3rd when insider Fouad Namouni sold 3,633 shares worth more than $324,499.56. Insiders at Blueprint Medicines own 4.2% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 10/3/2024.

Christopher K. Murray Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2024	Sell	621	$93.65	$58,156.65	36,374
2/28/2024	Sell	5,000	$100.00	$500,000.00	24,495
12/7/2023	Sell	5,000	$75.00	$375,000.00	24,495
12/4/2023	Sell	600	$71.43	$42,858.00	24,495
10/26/2023	Sell	600	$56.40	$33,840.00	25,095
3/6/2023	Sell	1,875	$45.68	$85,650.00	25,695
8/4/2022	Sell	2,500	$60.44	$151,100.00	21,320

Christopher K. Murray Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $94.81

$92.66

$95.02

50 Day Range

MA: $90.00

$82.47

$101.39

2 Week Range

Now: $94.81

$64.79

$121.90

Volume

566,224 shs

Average Volume

692,467 shs

Market Capitalization

$6.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

War on Elon Escalates…

From Porter & Company | Ad

One company holds a near-total monopoly on it.

Christopher Murray Biography and Net Worth

What is Christopher K. Murray's net worth?

How old is Christopher K. Murray?

What is Christopher K. Murray's salary?

How do I contact Christopher K. Murray?

Has Christopher K. Murray been buying or selling shares of Blueprint Medicines?

Who are Blueprint Medicines' active insiders?

Are insiders buying or selling shares of Blueprint Medicines?